LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change of Board ro.
Poolbeg Pharma (LON:POLB, OTCQB: POLBF) announces a change in Board role and the approval of an Employee Performance Incentive Plan to align objectives and encourage retention. Cathal Friel becomes Executive Chairman, bringing valuable experience from his successful track record in public companies. The plan aims to reward and retain key senior management for sustainable growth.